- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06077227
Immersive Heilung: Das therapeutische Potenzial der virtuellen Realität
Immersive Heilung: Das therapeutische Potenzial der virtuellen Realität in der Erfahrung von Phantomgliedern
Phantom limb pain (PLP) is a significant and pervasive issue among upper limb amputees, severely impacting their quality of life. The literature delineating prevalence of upper versus lower limb amputations is limited, but the prevalence of total amputations in the United States is estimated to reach 3 million individuals by 2050, with approximately 185,000 new cases annually. PLP affects 60-68% of these patients, leading to heightened levels of anxiety, depression, and reduced overall well-being.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Although studies exploring the efficacy of VR therapy for PLP have reported positive outcomes, several limitations, such as small sample sizes, lack of randomization, and inconsistent treatment protocols, have impeded widespread adoption of these innovative approaches. Additionally, the literature does not sufficiently delineate which aspects of the phantom limb experience may be addressed with VR therapy. To overcome these limitations and optimize treatment efficacy, it is crucial to gain a comprehensive understanding of the phantom limb experience, including both somatosensory and kinesthesia-related symptoms. Additionally, this study will address these limitations by employing a larger sample size, rigorous methodology, and a standardized treatment protocol.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
North Carolina
-
Charlotte, North Carolina, Vereinigte Staaten, 28207
- OrthoCarolina Hand Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- History of major limb amputation
- Age > 18 years old
- Presence of phantom limb pain or negative phantom sensation(s)
Exclusion Criteria:
- Active mental illness, neurological disease, or cognitive impairment that would interfere with survey completion
- Those without phantom limb pain or negative phantom limb sensations
- Non-English speaking
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Virtual Reality (VR) Intervention
Individuals undergoing virtual reality therapy intervention |
6 2 times weekly sessions of 30-minute VR therapy in the office with pre- and post-intervention surveys
Andere Namen:
|
|
Schein-Komparator: Matched Control
The matched controls will receive standard care without the VR intervention |
taking the same surveys as the VR intervention group on a weekly basis for 6 weeks
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Phantom limb pain levels using Short-form McGill Pain Questionnaire (SF-MPQ)
Zeitfenster: Baseline
|
Short-form McGill Pain Questionnaire - The maximum score an individual can reach on the MPQ is 78. According to the questionnaire, a person with a score of 0 effectively does not experience pain. A person with a high score, nearer to the highest score of 78, more than likely deals with chronic pain daily. |
Baseline
|
|
Phantom limb pain levels using Short-form McGill Pain Questionnaire (SF-MPQ)
Zeitfenster: Week 1
|
Short-form McGill Pain Questionnaire - The maximum score an individual can reach on the MPQ is 78. According to the questionnaire, a person with a score of 0 effectively does not experience pain. A person with a high score, nearer to the highest score of 78, more than likely deals with chronic pain daily. |
Week 1
|
|
Phantom limb pain levels using Short-form McGill Pain Questionnaire (SF-MPQ)
Zeitfenster: Week 2
|
Short-form McGill Pain Questionnaire - The maximum score an individual can reach on the MPQ is 78. According to the questionnaire, a person with a score of 0 effectively does not experience pain. A person with a high score, nearer to the highest score of 78, more than likely deals with chronic pain daily. |
Week 2
|
|
Phantom limb pain levels using Short-form McGill Pain Questionnaire (SF-MPQ)
Zeitfenster: Week 3
|
Short-form McGill Pain Questionnaire - The maximum score an individual can reach on the MPQ is 78. According to the questionnaire, a person with a score of 0 effectively does not experience pain. A person with a high score, nearer to the highest score of 78, more than likely deals with chronic pain daily. |
Week 3
|
|
Phantom limb pain levels using Short-form McGill Pain Questionnaire (SF-MPQ)
Zeitfenster: Week 6
|
Short-form McGill Pain Questionnaire - The maximum score an individual can reach on the MPQ is 78. According to the questionnaire, a person with a score of 0 effectively does not experience pain. A person with a high score, nearer to the highest score of 78, more than likely deals with chronic pain daily. |
Week 6
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Brief Pain Inventory (BPI) scores
Zeitfenster: Hour 24
|
Worst Pain Score: 1 - 4 = Mild Pain. Worst Pain Score: 5 - 6 = Moderate Pain. Worst Pain Score: 7 - 10 = Severe Pain - Scores range from 0 to 10 with higher scores indicating greater pain interference. |
Hour 24
|
|
Change in Short-Form McGill Pain Questionnaire (SF-MPQ) scores
Zeitfenster: Week 6
|
A short form of the McGill Pain Questionnaire (SF-MPQ) has been developed. The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Consists of 22 different descriptors of pain and each item is rated based on a 0-10 scale with 0 equal to no pain and 10 equal to the worst pain ever during the past week. The total score is calculated by summing 22 individual scores. |
Week 6
|
|
Phantom Limb Experience Survey score
Zeitfenster: Baseline
|
it is qualitative and there is no good or bad, this is just to define the population and better characterize phantom limb experience - assesses presence, onset, location, character, intensity, triggers, and treatment of phantom limb sensations and phantom limb pain. Includes questions on phantom limb posture, movement, size changes, and telescoping. |
Baseline
|
|
Change in Virtual Reality (VR) Therapy Survey scores
Zeitfenster: Week 6
|
There are several questions within this survey to assess attitude towards VR, which activities are favored and then the effect VR had on them. There is a mix of qualitative questions and quantitative. Quantitative questions are on Likert Scale 1-5. An interval change of +1 on Likert scale would be "good" for question on posture, control over limb. For how long the therapy effect lasts after session is over, it will vary from hours to days to weeks (which is why all descriptors are in there). Even if it lasted 1 hour this would be considered "good". |
Week 6
|
|
System Usability Scale
Zeitfenster: Week 6
|
Assesses subjective usability and satisfaction with the VR system - A perfect score of 100% signifies flawless usability and an exceptional user experience. The average SUS score is 68, and scores up to 70% are generally considered good; a good sus score indicates a decent level of usability. |
Week 6
|
|
Simulator Sickness Questionnaire
Zeitfenster: Week 6
|
negligible (< 5), minimal (5 - 10), significant (10 - 15), and concerning (15 - 20) symptoms. A simulator resulting in total scores above 20 is considered "bad" |
Week 6
|
|
Change in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) scores
Zeitfenster: Week 6
|
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.EQ-5D-5L index scores range from -0.59 to 1, where 1 is the best possible health state |
Week 6
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Glenn Gaston, MD, Atrium Health Musculoskeletal Institute
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Schmerzen
- Neurologische Manifestationen
- Erkrankungen des Nervensystems
- Postoperative Komplikationen
- Pathologische Prozesse
- Neurobehaviorale Manifestationen
- Wahrnehmungsstörungen
- Schmerzen, postoperativ
- Pathologische Zustände, Anzeichen und Symptome
- Anzeichen und Symptome
- Agnosie
- Phantomglied
- Untersuchungstechniken
- Epidemiologisches Forschungsdesign
- Epidemiologische Methoden
- Forschungsdesign
- Methoden
- Kontrollgruppen
Andere Studien-ID-Nummern
- IRB00100006
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Individual Participant Data that underlie the results reported in this article, after deidentification
IPD-Sharing-Zeitrahmen
Beginning 3 months and ending 5 years following article publication
IPD-Sharing-Zugriffskriterien
Researchers who provide a methodologically sound proposal
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ANALYTIC_CODE
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .